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Abstract
Objective:  To  assess  clinical  and  laboratory  data,  and  acute  kidney  injury  (AKI)  in  HIV-infected
children using  and  not  using  highly  active  antiretroviral  therapy  (HAART)  prior  to  admission.
Methods:  A  retrospective  study  was  conducted  with  HIV-infected  pediatric  patients  (<16  years).
Children who  were  using  and  not  using  HAART  prior  to  admission  were  compared.
Results:  Sixty-three  patients  were  included.  Mean  age  was  5.3  ±  4.27  years;  55.6%  were
females.  AKI  was  observed  in  33  (52.3%)  children.  Patients  on  HAART  presented  lower  lev-
els of  potassium  (3.9  ±  0.8  vs.  4.5  ±  0.7  mEq/L,  p  =  0.019)  and  bicarbonate  (19.1  ±  4.9  vs.
23.5 ±  2.2  mEq/L,  p  =  0.013)  and  had  a  higher  estimated  glomerular  ﬁltration  rate  (102.2  ±  36.7
vs. 77.0  ±  32.8  mL/min/1.73  m2,  p  =  0.011)  than  those  not  on  HAART.  In  the  multivariate  analy-
sis, the  use  of  HAART  prior  to  the  admission  was  a  protective  factor  for  AKI  (p  =  0.036;  OR  =  0.30;
95% CI  =  0.097--0.926).
Conclusion:  AKI  is  a  common  complication  of  pediatric  HIV  infection.  Use  of  HAART  prior  to  the
admission  preserved  glomerular  ﬁltration  and  was  a  protective  factor  for  AKI,  but  increased
medication  side  effects,  such  as  hypokalemia  and  renal  metabolic  acidosis.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Lesão  renal  aguda  em  crianc¸as com  HIV:  estudo  comparativo  entre  pacientes  com  e
sem  terapia  antirretroviral  altamente  ativa
Resumo
Objetivo:  Avaliar  dados  clínicos  e  laboratoriais,  bem  como  ocorrência  de  lesão  renal  aguda
(LRA) em  crianc¸as  HIV  positivas  com  e  sem  uso  de  terapia  antirretroviral  altamente  ativa  (TARV)
antes da  admissão.
Método:  Foi  realizado  estudo  retrospectivo  em  pacientes  pediátricos  HIV  positivos  (<16  anos).
Foram comparadas  as  crianc¸as  que  estavam  em  uso  com  aquelas  sem  uso  de  TARV  prévia  à
internac¸ão.
Resultados:  Foram  incluídos  63  pacientes,  com  média  de  idade  de  5,3  ±  4,27  anos,  sendo  55,6%
do sexo  feminino.  LRA  foi  encontrada  em  33  casos  (52,3%).  Os  pacientes  usando  TARV  apre-
sentaram  menores  níveis  de  potássio  (3,9  ±  0,8  vs.  4,5  ±  0,7  mEq/L,  p  =  0,019)  e  bicarbonato
(19,1 ±  4,9  vs.  23,5  ±  2,2  mEq/L,  p  =  0,013),  bem  como  maior  taxa  de  ﬁltrac¸ão  glomerular
estimada  (102,2  ±  36,7  vs.  77,0  ±  32,8  mL/min/1,73m2,  p  =  0,011)  que  o  pacientes  sem  TARV
prévia. Na  análise  multivariada  o  uso  de  TARV  prévia  à  internac¸ão  foi  fator  protetor  contra  LRA
(p =  0,036;  RC  =  0,30;  IC  de  95%  =  0,097-0,926).
Conclusão:  A  LRA  é  uma  complicac¸ão  comum  da  infecc¸ão  pediátrica  pelo  HIV.  O  uso  de  TARV
antes da  internac¸ão  foi  associado  a  melhor  taxa  de  ﬁltrac¸ão  glomerular  e  foi  fator  de  protec¸ão
contra LRA,  porém  desencadeou  efeitos  colaterais  como  hipocalemia  e  acidose  metabólica.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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oratory  data,  dialysis  requirement,  and  mortality.  Clinicalntroduction
ccording  to  the  United  Nations  Program  on  HIV/AIDS
UNAIDS),  it  was  estimated  that  approximately  35  million
eople  worldwide  were  living  with  HIV  or  acquired  immune
eﬁciency  syndrome  (AIDS)  in  2012.  Furthermore,  the  2012
nnual  number  of  new  HIV  infections  was  calculated  to  be
early  2.5  million.  Over  12%  of  them  (330,000  cases  world-
ide)  occurred  in  the  pediatric  population  younger  than
5  years.  In  2011,  230,000  children  died  due  to  HIV/AIDS
orldwide.1
The  prevalence  of  renal  diseases  in  HIV-infected  pediatric
atients  varies  substantially  among  regions  and  periods.
n  the  pre-Highly  Active  Antiretroviral  Therapy  (HAART)
ra,  most  of  the  infected  children  in  the  United  States
ied  of  non-renal  AIDS  complications,  such  as  opportunistic
nfections  (OIs).  This  phenomenon  is  still  common  in  some
eveloping  countries,  where  this  therapy  is  not  available
o  all  patients.  However,  after  the  establishment  of  HAART
n  developed  countries,  the  number  of  HIV-infected  chil-
ren  who  require  renal  replacement  therapy  has  increased
onsiderably.2 Kidney  disease  complicating  HIV  infection  is
ow  among  the  10  most  common  non-infectious  conditions
ccurring  in  perinatally  HIV-infected  children  and  adoles-
ents  in  the  HAART  era,  with  an  incidence  rate  of  2.6  per
00  patients.3
HIV  patients  are  at  high  risk  of  developing  both  acute
idney  injury  (AKI)  and  chronic  kidney  disease  (CKD)  due
o  several  factors.4 In  this  context,  the  spectrum  of
idney  diseases  in  HIV-infected  pediatric  population  is
ifferent  from  adults,  including  chronic  glomerular  dis-
rders,  such  as  HIV-associated  nephropathy;  HIV  immune
omplex  kidney  disease;  some  types  of  thrombotic  microan-
iopathies,  such  as  atypical  forms  of  hemolytic  uremic
i
s
hyndrome  and  thrombocytopenic  purpura;  tubular  disorders;
nd  AKI.5
The  aim  of  this  study  was  to  evaluate  clinical  and  lab-
ratory  data,  as  well  as  the  occurrence  of  AKI,  using  the
odiﬁed  pediatric  RIFLE  (pRIFLE)  criteria  in  HIV-infected
hildren,  by  comparing  groups  according  to  the  use  of  HAART
rior  to  hospital  admission.
atients and methods
etting  and  patient  selection
his  was  a  retrospective  study  performed  with  HIV-infected
hildren  consecutively  admitted  to  São  José  Infectious  Dis-
ases  Hospital,  Northeast  Brazil,  from  January  2007  to
ecember  2012.  All  children  younger  than  16  years  with
onﬁrmed  serology  for  HIV  infection  were  included.  This  is
he  same  age  range  for  which  the  Schwartz  equation  was
alidated.6 Patients  with  history  of  previous  renal  diseases,
rterial  hypertension,  diabetes  mellitus,  nephrolithiasis,  use
f  nephrotoxic  drugs  (except  for  HAART),  and  other  co-
orbidities  that  could  affect  renal  function  were  excluded.
tudied  parameters
emographic  characteristics  such  as  age  and  gender  were
nalyzed,  as  well  as  duration  of  hospital  stay,  co-infections,
se  of  HAART,  and  clinical  manifestations  on  admission,  lab-nvestigations  included  a  record  of  all  clinical  signs  and
ymptoms  presented  by  patients  at  admission  and  during
ospital  stay.
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Laboratory  data  included  assessments  of  serum  cre-
atinine  (Cr),  urea  (Ur),  sodium  (Na),  potassium  (K),
albumin  (Alb),  alanine  aminotransferase  (ALT),  aspar-
tate  aminotransferase  (AST),  lactate  dehydrogenase  (LDH),
hemoglobin  (Hb),  hematocrit  (Ht),  platelets,  leukocytes,
lymphocytes,  serum  pH  (pH),  CO2 partial  pressure  (pCO2),
bicarbonate  (HCO3),  urine  pH,  and  urine  density.  Mean
viral  load  (VL)  and  CD4  count  were  also  evaluated.
VL  =  100,000  copies/mm3 and  CD4  count  =  200/mm3 were
established  as  cut  off  points  in  order  to  compare  HAART
and  non-HAART  patients,  since  these  values  were  previously
associated  with  development  of  AKI  and  poor  outcomes.7
Deﬁnitions
Acute  Kidney  Injury  was  deﬁned  according  to  pediatric
RIFLE  (pRIFLE)  criteria,  using  Schwartz  equation  to  esti-
mate  glomerular  ﬁltration  rate  (eGFR).6 pRIFLE  categories
include:8,9
-  Risk:  eGFR  reduction  by  25%  or  urine  output  <  0.5  mL/kg/h
for  8  h.
-  Injury:  eGFR  reduction  by  50%  or  urine  out-
put  <  0.5  mL/kg/h  for  16  h.
-  Failure:  eGFR  reduction  by  75%  or  eGFR  <  35  mL/
min/1.73  m2 or  urine  output  <  0.3  mL/kg/h  for  24  h  or
anuric  for  12  h.
-  Loss:  persistent  failure  >  four  weeks.
-  End-stage  renal  disease:  persistent  failure  >  three  months.
A  baseline  eGFR  of  120  mL/min/m2 was  assigned  to
all  children  as  previously  reported,  since  none  of  them
had  available  serum  creatinine  levels  measured  within
three  months  before  admission.8,9 eGFR  was  calculated  by
using  serum  creatinine  on  hospital  admission.  The  percent-
age  of  eGFR  reduction  [100  ×  (baseline  eGFR  −  admission
eGFR)/baseline  eGFR]  was  assessed  to  determine  pRIFLE
category.  Patients  were  classiﬁed  according  pRIFLE  cate-
gory  on  admission.  Due  to  the  absence  of  anthropometric
data  in  charts,  mean  height  for  each  age  and  gender  was
obtained  from  World  Health  Organization  (WHO)  Growth
data,  in  order  to  calculate  eGFR.10,11
Oliguria  was  deﬁned  as  urine  output  <1  mL/kg/h  in
infants  (0--12  months)  and  <0.5  mL/kg/h  in  children  who  had
been  effectively  hydrated.  Dialysis  was  indicated  in  those
patients  that  remained  oliguric  after  effective  hydration,  in
those  cases  where  uremia  was  associated  with  hemorrhagic
or  severe  respiratory  failure,  and  those  with  hyperkalemia  or
metabolic  acidosis  refractory  to  clinical  treatment.  Dialysis
was  indicated  in  those  patients  who  remained  oliguric  after
effective  hydration,  in  rapid  elevation  of  blood  urea  nitro-
gen  (hypercatabolic  state),  in  those  cases  where  uremia  was
associated  to  hemorrhagic  or  severe  respiratory  failure,  and
those  with  hyperkalemia  or  metabolic  acidosis  refractory  to
clinical  treatment.Children  were  divided  into  two  groups:  those  who  were
in  use  of  HAART  prior  to  the  admission  and  those  who  were
not.  Demographical,  clinical,  and  laboratory  data  of  the  two
groups  were  compared.
t
r
s
t633
reatment
he  HAART  drugs  used  in  the  treatment  were:  zidovu-
ine  (AZT),  didanosine  (ddI),  lamivudine  (3TC),  stavudine
D4T),  abacavir  (ABC),  tenofovir  disoproxil  fumarate  (TDF),
opinavir  (LPV),  nelﬁnavir  (NFV),  saquinavir  (SQV),  ritonavir
RTV),  amprenavir  (APV),  efavirenz  (EFZ),  and  nevirapine
NPV),  according  to  the  protocols  of  the  Brazilian  Ministry
f  Health.
tatistical  analysis
he  SPSS  software  for  Windows,  release  20.0  (IBM  Corp.
eleased  2011.  IBM  SPSS  Statistics  for  Windows,  version  20.0,
SA)  was  used  for  statistical  analysis.  Chi-squared  test  was
sed  to  analyze  frequencies  in  the  patients’  groups.  All
ndependent  variables  were  tested  for  normal  distribution
sing  the  Kolmogorov--Smirnov  test.  Differences  between
wo  independent  variables  were  evaluated  using  Student’s
-test  or  Mann--Whitney  test  as  appropriate.  Data  were
xpressed  as  means  ±  SD,  and  a  p  ≤  0.05  was  considered  sta-
istically  signiﬁcant.
A  multivariate  logistic  regression  was  performed  to  ana-
yze  the  possible  risk  factors  associated  with  AKI.  Initially,
 univariate  analysis  was  done  with  all  dichotomous  varia-
les  available,  including  gender,  presence  of  each  symptom
nd  comorbidity,  HAART  use,  viral  load  >100,000  copies,  and
D4  count  <200/mm3.  These  parameters  were  evaluated
or  signiﬁcant  difference  between  AKI  and  non-AKI  groups,
sing  the  chi-squared  test  and  crosstabs.  Secondly,  param-
ters  included  in  the  multivariate  model  were  those  that
resented  a  signiﬁcance  level  (p  ≤  0.05)  in  the  univariate
nalysis.  Only  one  of  them  (HAART  use)  was  signiﬁcantly
ifferent,  so  it  was  evaluated  as  a  risk  factor  for  AKI,  by
alculating  the  adjusted  odds  ratio  (OR)  and  95%  conﬁdence
nterval  (95%  CI).
thics
he  study  protocol  was  reviewed  and  approved  by  Ethics
ommittees  from  Walter  Cantídio  University  Hospital  and
ão  José  Infectious  Diseases  Hospital.
esults
ixty-three  children  were  included,  with  mean  age
.3  ±  4.27  years  (range  1--14  years);  44  (69.8%)  were  younger
han  7  years;  35  ﬁve  (55.6%)  were  females.  Forty-three
68.3%)  patients  were  using  HAART  prior  to  admission,  while
0  (31.7%)  were  not.  Among  all  patients  using  HAART,  37
58.7%)  were  using  3TC;  31  (49.2%),  AZT.  16  (35.4%),  LPV;
nd  ﬁve  (7.9%)  TDF.  Duration  of  hospital  stay  ranged  from
 to  352  days  (mean  34.2  ±  57.8  days).  One  patient  needed
emodialysis  (3.2%)  and  one  patient  died  (3.2%).  None  of
he  patients  needed  intensive  care.  Only  16  children  had
rine  samples.  One  of  them  presented  microscopic  hema-
uria  and  three  presented  proteinuria,  none  in  the  nephrotic
ange  of  proteinuria.  Comparison  of  demographic  data,  main
igns  and  symptoms,  associated  infections,  immunologic  sta-
us  and  outcomes  between  the  two  groups  is  summarized
634  Soares  DS  et  al.
Table  1  Demographic  data,  clinical  manifestations,  infection  status,  and  outcomes  of  children  with  human  immunodeﬁciency
virus (HIV)  according  to  the  use  of  highly  active  antiretroviral  therapy  (HAART).
HAART  (n  =  43)  Non-HAART  (n  =  20)  p
Age  (years)  6.3  ±  4.1  3.1  ±  3.8  0.002
Gender
Males 20  (46.6%)  12  (60%)  0.786
Females 23  (53.4%)  8  (40%)  0.786
Hospital stay  (days) 35.4  ±  66.2 31.4  ±  33.2  0.088
Signs and  symptoms  (%)
Fever  35  (81.3%) 17  (85%) 1.000
Cough 30  (69.7%) 13  (65%) 0.775
Dyspnea 16  (37.2%)  6  (30%)  0.777
Diarrhea 16  (37.2%)  7  (35%)  1.000
Vomiting 15  (34.8%)  3  (15%)  0.139
Weight loss 3  (6.9%) 3  (15%) 0.372
Associated infections  (%)
Pneumonia  20  (46.6%)  8  (40%)  0.786
Tuberculosis 3  (6.9%)  3  (15%)  0.372
Varicella 3  (6.9%)  1  (5%)  1.000
Infection status  (%)
Mean  viral  load  >  100,000  copies/mm3 9  (20.9%)  9  (45%)  0.124
CD4 lymphocytes  <  200/mm3 6  (13.9%)  6  (30%)  0.162
Outcomes (%)
Dialysis  1  (2.3%)  0  1.000
Death 1  (2.3%)  0  1.000
Age and hospital stay are presented as mean ± SD. The rest of the data are presented as number (percentage). Student’s t-test and the
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achi-squared test were used. p-values ≤ 0.05 were considered stat
n  Table  1.  Among  all  patients,  the  most  frequent
pportunistic  infections  (OIs)  were  pneumonia  (44.4%),  pul-
onary  tuberculosis  (9.5%),  and  varicella  zoster/chickenpox
6.3%).
Comparing  groups,  it  was  noticed  that  those  patients
n  HAART  presented  signiﬁcantly  lower  levels  of  serum
icarbonate  (19.1  ±  4.9  vs.  23.6  ±  2.2  mEq/L,  p  =  0.013)  and
erum  potassium  (3.9  ±  0.8  vs.  4.5  ±  0.7  mEq/L,  p  =  0.019)
han  those  not  on  HAART,  respectively.  Also,  those  patients
ot  on  HAART  presented  signiﬁcantly  higher  levels  of
ST  (123.1  ±  189.9  U/L  vs.  39.8  ±  26.7,  p  =  0.008)  and  ALT
77.9  ±  102.8  U/L  vs.  25.3  ±  21.5,  p  =  0.001)  than  those
n  HAART,  respectively.  Moreover,  eGFR  was  remarkably
igher  in  patients  on  HAART  than  in  those  not  on  HAART
102.2  ±  36.7  vs.  77.0  ±  32.8  mL/min/1.73  m2, p  =  0.011).
here  was  no  signiﬁcant  difference  between  the  two  groups
hen  comparing  percentage  of  patients  who  presented
D4  <  200/mm3 and  VL  >  100,000  copies/mm3.  A  compari-
on  of  laboratory  data  between  groups  is  presented  in
able  2.
AKI  was  observed  in  33  (52.3%)  children.  Nineteen  were
lassiﬁed  as  Risk  (57.5%),  13  as  injury  (39.4%),  and  one
s  failure  (3.1%).  Prevalence  of  AKI  was  lower  in  those  on
AART  than  those  not  on  HAART  (41.86%  vs.  75%,  p  =  0.037).
n  the  multivariate  analysis,  use  of  HAART  prior  to  admission
as  a  protective  factor  for  AKI  (p  =  0.036;  OR  =  0.30;  95%
I  =  0.097--0.926).  Comparison  of  AKI  prevalence  between
roups  is  shown  in  Table  3.
d
f
t
olly signiﬁcant.
iscussion
his  was  the  ﬁrst  study  to  evaluate  demographical,  clini-
al,  and  laboratory  data  of  HIV-infected  children  admitted  to
n  infectious  diseases  hospital  in  Fortaleza,  state  of  Ceará,
razil,  focusing  on  renal  function  and  the  development  of
KI.  It  was  observed  that  HAART  appears  to  be  a  protective
actor  against  AKI  in  children  with  HIV.
In  the  present  study,  mean  age  of  the  children  was  5.3
ears,  with  a  predominance  of  females,  which  is  similar  to
ast  studies  that  evaluated  renal  disease  in  HIV-infected
hildren.12--14 Furthermore,  the  most  prevalent  symptoms  in
he  present  study  were  fever  and  cough,  which  reﬂect  main
ssociated  infections,  the  leading  cause  of  hospitalization.
n  two  recent  pediatric  studies,  the  main  symptoms  were
dentical  to  those  of  the  present  cohort.15,16 Regarding  viral
nd  immunologic  status,  most  patients  presented  high  lev-
ls  of  mean  viral  load  and  low  CD4  count,  but  there  was  not
igniﬁcant  difference  between  groups.
Among  all  children  in  the  present  study,  hypokalemia
as  observed  in  22.2%  of  them.  Mean  serum  potassium
as  signiﬁcantly  lower  in  patients  on  HAART  than  in  those
ot  on  HAART.  This  electrolyte  disorder  has  been  associ-
ted  with  antiretroviral  use,  especially  TDF,  most  likely
ue  to  its  well-known  nephrotoxicity.17,18 In  a  study  per-
ormed  by  Kohler  et  al.,  it  was  observed  that  TDF’s  renal
oxicity  and  the  hypokalemia  that  follows  happen  because
f  the  renal  proximal  tubular  mitochondrial  ultrastructural
Acute  kidney  injury  in  HIV-infected  children  635
Table  2  Comparison  of  laboratory  data  between  children  with  human  immunodeﬁciency  virus  (HIV)  according  to  use  of  highly
active antiretroviral  therapy  (HAART).
HAART  (n  =  43) Non-HAART  (n  =  20) p
Mean  viral  load  (103 copies/mm3)  82.18  ±  143.93  209.01  ±  223.14  0.157
CD4 count  (/mm3)  695.7  ±  615.6  875.5  ±  928.6  0.472
pH 7.3  ±  0.2  7.4  ±  0.1  0.548
PCO2 (mmHg)  33.2  ±  13.0  36.3  ±  3.2  0.486
HCO3 (mEq/L)  19.1  ±  4.9  23.6  ±  2.2  0.013
Na (mEq/L) 135.5  ±  4.4  136.5  ±  2.5  0.374
K (mEq/L) 3.9  ±  0.8 4.5  ±  0.7 0.019
Hb (g/dL) 9.8  ±  1.7 9.2  ±  1.2 0.141
Ht (%) 29.9  ±  4.5 28.7  ±  3.7 0.295
Leukocytes  (/mm3)  9175.2  ±  6234.3  9448.6  ±  6120.1  0.872
Lymphocytes  (/mm3)  2402.1  ±  1542.7  3519.4  ±  2977.4  0.128
Platelets (103/mm3)  279.19  ±  132.60  211.75  ±  127.41  0.063
LDH (U/L)  710.3  ±  583.8  1134.5  ±  1562.3  0.364
Ur (mg/dL)  22.5  ±  11.3  28.2  ±  15.1  0.107
Cr (mg/dL)  0.5  ±  0.19  0.52  ±  0.2  0.781
Albumin (g/dL)  3.6  ±  0.6  3.7  ±  0.5  0.594
AST (U/L)  39.8  ±  26.7  123.1  ±  189.9  0.008
ALT (U/L)  25.3  ±  21.5  77.9  ±  102.8  0.001
eGFR (mL/min/1.73  m2)  102.2  ±  36.7  77.0  ±  32.8  0.011
Data are presented as mean ± SD.
pH, serum hydrogenionic potential; PCO2, carbon dioxide partial pressure; HCO3, serum bicarbonate; Na, serum sodium; K, serum
potassium; Hb, serum hemoglobin; Ht, hematocrit; LDH, lactate dehydrogenase; Ur, serum urea; Cr, serum creatinine; Albumin, serum
albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular ﬁltration rate. Student’s t-test
and Mann--Whitney tests were used. p-values ≤ 0.05 were considered s
Table  3  Comparison  of  acute  kidney  injury  (AKI)  preva-
lence according  to  use  of  highly  active  antiretroviral  therapy
(HAART).
HAART
(n  =  43)
Non-HAART
(n  =  20)
p
AKI  18  (41.86%)  15  (75%)  0.037
Non-AKI  25  (58.14%)  5  (25%)
Data were presented as number (percentage). The chi-squared
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including  sepsis,  nephrotoxic  drugs,  volume  depletion,  andtest was used.
p-values ≤ 0.05 were considered statistically signiﬁcant.
abnormalities  induced  by  this  drug.19 In  addition,  lower
body  weight  and  high-dose  of  the  drug  were  signiﬁcantly
associated  with  TDF-induced  nephrotoxicity  in  HIV-infected
children  from  the  United  Kingdom.20
In  addition  to  hypokalemia,  lactic  acidosis  has  also  been
reported  as  a  consequence  of  HAART  toxicity,  speciﬁcally  by
the  nucleoside  reverse  transcriptase  inhibitors  (NRTIs).  This
is  an  important  cause  of  acidosis  in  HIV-infected  patients,
both  children  and  adults.21,22 In  the  present  study,  lower
mean  levels  of  serum  bicarbonate  were  observed  in  patients
on  HAART  than  in  those  not  on  HAART,  which  indicates  higher
incidence  of  metabolic  acidosis  in  the  ﬁrst  group.  Further-
more,  mitochondrial  toxicity  in  proximal  tubule  cells  is  the
responsible  for  another  well-described  cause  of  acidosis  in
HIV  patients  using  HAART:  Fanconi  syndrome.23,24 Hence,
HAART  toxicity  is  most  likely  the  major  cause  of  metabolic
acidosis  in  the  present  cohort  instead  of  eGFR  decrease,
u
atatistically signiﬁcant.
ince  serum  bicarbonate  was  lower  in  patients  on  HAART,
ho  presented  higher  levels  of  eGFR.
Other  interesting  ﬁndings  in  the  present  study  were  the
igher  mean  levels  of  AST  and  ALT  in  patients  not  on  HAART
hen  compared  to  those  on  HAART,  which  may  indicate
iver  injury.  According  to  a  recent  review  of  liver  disease
n  HIV-infected  adult  patients,  there  are  several  factors
elated  to  liver  injury  and  HIV,  including  hepatitis  B  and  C
iruses  co-infection;  steatosis  and  non-alcoholic  steatohep-
titis  (NASH);  metabolic  changes  such  as  insulin  resistance;
iver  toxicity  of  the  medications,  especially  HAART;  and  also
 direct  effect  of  the  HIV  on  the  liver.25 Some  of  these  factors
robably  contributed  to  AST  and  ALT  elevation  in  the  present
ohort.  Since  higher  levels  of  liver  enzymes  were  presented
y  the  patients  who  were  not  on  HAART,  liver  impairment  is
ost  likely  due  to  causes  other  than  drug  toxicity.
Since  the  introduction  of  HAART,  chronic  conditions  such
s  renal  disease  have  been  rising  as  important  causes  of
orbidity  and  mortality  of  patients  with  HIV.  In  the  present
tudy,  it  was  observed  that  those  not  on  HAART  presented  an
mportant  renal  function  impairment  and  higher  incidence
f  AKI  when  compared  to  patients  on  HAART.  In  addition,
KI  is  a  common  complication  in  ambulatory  HIV-infected
dult  patients  treated  with  HAART,  having  been  associated
ith  previous  renal  impairment,  lower  CD4  levels,  AIDS,
epatitis  C  virus  co-infection  and  liver  disease.26,27 Usually,
he  development  of  AKI  in  these  patients  is  multifactorial,se  of  radiocontrast.28
In  the  multivariate  analysis,  use  of  HAART  prior  to  the
dmission  was  a  protective  factor  for  AKI.  This  might  be
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xplained  by  the  beneﬁts  of  HAART  in  reducing  viral  load
nd  then  decreasing  renal  effects  of  HIV.  There  is  evidence
o  prove  the  efﬁcacy  of  HAART  in  preventing  HIV-associated
ephropathy  and  delaying  progression  to  end-stage  renal
isease  in  HIV-infected  adult  patients.29,30
In  conclusion,  renal  disease  is  rising  as  an  important
ong-term  complication  of  HIV  infection  in  children  world-
ide.  The  comparison  between  the  two  groups  showed  that
hildren  using  HAART  prior  to  the  admission  had  higher
GFR,  but  lower  levels  of  potassium  and  bicarbonate.  HAART
se  was  shown  to  be  a  protective  factor  for  AKI.  These
ndings  may  indicate  that  the  use  of  HAART  prior  to  the
dmission  preserved  glomerular  ﬁltration  and  reduced  inci-
ence  of  AKI,  but  increased  medication  side  effects,  such  as
ypokalemia  and  renal  metabolic  acidosis,  which  are  mainly
ssociated  with  some  antiretorvirals,  such  as  TDF.
tudy limitations
tudy  limitations  include  some  data  missing  due  to  the
etrospective  nature  of  the  research,  and  the  sample  selec-
ion,  which  was  based  only  on  hospitalized  patients.  The
uthors  did  not  have  access  to  data  on  children’s  urine
utput,  as  this  was  a  retrospective  study.  In  general,  non-
ritical  care  units  do  not  accurately  record  urine  output,
specially  in  the  pediatric  population.  Some  anthropometric
ata,  such  as  height  and  weight,  were  also  not  available  in
hildren’s  charts,  so  it  was  necessary  to  obtain  some  of  them
rom  WHO  Growth  Data  in  order  to  estimate  GFR  by  using
chwartz  formula.  Duration  of  HAART  was  also  not  available
n  patient’s  records.  Serum  creatinine  within  three  months
efore  admission  was  also  not  available,  thus  a  baseline
GFR  of  120  mL/min/1.73  m2 was  assumed  for  all  children,
ince  they  did  not  present  any  identiﬁed  factors  for  previous
hronic  kidney  disease  and  it  was  not  possible  to  estimate
he  real  GFR.  Using  AKI  as  the  outcome  of  interest  may  have
educed  the  accuracy  of  logistic  regression  results,  since
he  number  of  AKI  patients  was  limited  (only  33),  but  did
ot  undermine  the  importance  of  the  multivariate  analysis
ndings.
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